Ziding Feng

List of Publications by Year
in descending order

170 papers	17,995 citations	16411 64 h-index	12910 131 g-index
171 all docs	171 docs citations	171 times ranked	22089 citing authors

#	Article	IF	Citations
1	Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. Journal of the National Cancer Institute, 2005, 97, 339-346.	3.0	2,194
2	Phases of Biomarker Development for Early Detection of Cancer. Journal of the National Cancer Institute, 2001, 93, 1054-1061.	3.0	1,431
3	Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute, 2006, 98, 529-534.	3.0	851
4	Association between Body-Mass Index and Risk of Death in More Than 1 Million Asians. New England Journal of Medicine, 2011, 364, 719-729.	13.9	730
5	Î±-Fetoprotein, Des-Î³ Carboxyprothrombin, and Lectin-Bound Î±-Fetoprotein in Early Hepatocellular Carcinoma. Gastroenterology, 2009, 137, 110-118.	0.6	644
6	Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Research, 2002, 62, 3609-14.	0.4	630
7	Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design. Journal of the National Cancer Institute, 2008, 100, 1432-1438.	3.0	597
8	Boosted Decision Tree Analysis of Surface-enhanced Laser Desorption/Ionization Mass Spectral Serum Profiles Discriminates Prostate Cancer from Noncancer Patients. Clinical Chemistry, 2002, 48, 1835-1843.	1.5	414
9	Diagnostic Markers for Early Detection of Ovarian Cancer. Clinical Cancer Research, 2008, 14, 1065-1072.	3.2	371
10	Evaluation of Serum Protein Profiling by Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry for the Detection of Prostate Cancer: I. Assessment of Platform Reproducibility. Clinical Chemistry, 2005, 51, 102-112.	1.5	336
11	Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology, 2012, 55, 483-490.	3.6	268
12	A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. Biostatistics, 2003, 4, 449-463.	0.9	254
13	Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene, 2005, 24, 4138-4148.	2.6	240
14	Association between body mass index and cardiovascular disease mortality in east Asians and south Asians: pooled analysis of prospective data from the Asia Cohort Consortium. BMJ, The, 2013, 347, f5446-f5446.	3.0	239
15	Integrating the Predictiveness of a Marker with Its Performance as a Classifier. American Journal of Epidemiology, 2007, 167, 362-368.	1.6	236
16	Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?. Journal of Clinical Oncology, 2014, 32, 4066-4072.	0.8	234
17	Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. Gastroenterology, 2018, 155, 730-739.e3.	0.6	215
18	A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus. Cancer Research, 2009, 69, 4112-4115.	0.4	202

#	ARTICLE	IF	CITATIONS
19	Occurrence of Autoantibodies to Annexin I, 14-3-3 Theta and LAMR1 in Prediagnostic Lung Cancer Sera. Journal of Clinical Oncology, 2008, 26, 5060-5066.	0.8	178
20	Body Mass Index and Diabetes in Asia: A Cross-Sectional Pooled Analysis of 900,000 Individuals in the Asia Cohort Consortium. PLoS ONE, 2011, 6, e19930.	1.1	154
21	Ulcerative Colitis Is a Disease of Accelerated Colon Aging: Evidence From Telomere Attrition and DNA Damage. Gastroenterology, 2008, 135, 410-418.	0.6	153
22	Seattle 5 a Day Worksite Program to Increase Fruit and Vegetable Consumption. Preventive Medicine, 2001, 32, 230-238.	1.6	150
23	Prevalidation of Salivary Biomarkers for Oral Cancer Detection. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 664-672.	1.1	150
24	Noninvasive Saliva-based *EGFR* Gene Mutation Detection in Patients with Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1117-1126.	2.5	146
25	Presence of simian virus 40 DNA sequences in human lymphomas. Lancet, The, 2002, 359, 851-852.	6.3	142
26	Antibody Microarray Profiling Reveals Individual and Combined Serum Proteins Associated with Pancreatic Cancer. Cancer Research, 2005, 65, 11193-11202.	0.4	141
27	Selected Statistical Issues in Group Randomized Trials. Annual Review of Public Health, 2001, 22, 167-187.	7.6	134
28	Prostate Cancer Specific Mortality and Gleason 7 Disease Differences in Prostate Cancer Outcomes Between Cases With Gleason 4 + 3 and Gleason 3 + 4 Tumors in a Population Based Cohort. Journal of Urology, 2009, 182, 2702-2707.	0.2	133
29	A COMPARISON OF STATISTICAL METHODS FOR CLUSTERED DATA ANALYSIS WITH GAUSSIAN ERROR. , 1996, 15, 1793-1806.		132
30	Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study. Clinical Cancer Research, 2013, 19, 2442-2450.	3.2	132
31	Polymorphisms, Mutations, and Amplification of the EGFR Gene in Non-Small Cell Lung Cancers. PLoS Medicine, 2007, 4, e125.	3.9	130
32	Baseline Fruit and Vegetable Intake among Adults in Seven 5 A Day Study Centers Located in Diverse Geographic Areas. Journal of the American Dietetic Association, 1999, 99, 1241-1248.	1.3	128
33	SELDI-TOF MS Whole Serum Proteomic Profiling with IMAC Surface Does Not Reliably Detect Prostate Cancer. Clinical Chemistry, 2008, 54, 53-60.	1.5	128
34	Analytical Validation of Serum Proteomic Profiling for Diagnosis of Prostate Cancer: Sources of Sample Bias. Clinical Chemistry, 2008, 54, 44-52.	1.5	126
35	Ulcerative Colitisâ€"Associated Colorectal Cancer Arises in a Field of Short Telomeres, Senescence, and Inflammation. Cancer Research, 2011, 71, 1669-1679.	0.4	123
36	Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. Journal of Urology, 2016, 195, 313-320.	0.2	122

#	ARTICLE	IF	CITATIONS
37	Association Between Combined *TMPRSS2:ERG* and *PCA3* RNA Urinary Testing and Detection of Aggressive Prostate Cancer. JAMA Oncology, 2017, 3, 1085.	3.4	120
38	Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. Journal of the National Cancer Institute, 2017, 109, djw266.	3.0	116
39	Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective. Pharmacogenomics, 2004, 5, 709-719.	0.6	115
40	Meat intake and cause-specific mortality: a pooled analysis of Asian prospective cohort studies. American Journal of Clinical Nutrition, 2013, 98, 1032-1041.	2.2	109
41	Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized. American Journal of Surgical Pathology, 2016, 40, 1439-1456.	2.1	107
42	An Automated Peak Identification/Calibration Procedure for High-Dimensional Protein Measures From Mass Spectrometers. Journal of Biomedicine and Biotechnology, 2003, 2003, 242-248.	3.0	103
43	Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clinical Chemistry, 2002, 48, 1835-43.	1.5	103
44	Optimized Normalization for Antibody Microarrays and Application to Serum-Protein Profiling. Molecular and Cellular Proteomics, 2005, 4, 773-784.	2.5	102
45	Evaluating the Predictiveness of a Continuous Marker. Biometrics, 2007, 63, 1181-1188.	0.8	102
46	Burden of Total and Cause-Specific Mortality Related to Tobacco Smoking among Adults Aged â‰¥45 Years in Asia: A Pooled Analysis of 21 Cohorts. PLoS Medicine, 2014, 11, e1001631.	3.9	98
47	International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology, 2021, 160, 2572-2584.	0.6	91
48	Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Nonâ€"Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B. Journal of Clinical Oncology, 2015, 33, 3880-3886.	0.8	88
49	Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Letters, 2007, 247, 56-71.	3.2	87
50	Use of Aspirin and Other Nonsteroidal Antiinflammatory Medications in Relation to Prostate Cancer Risk. American Journal of Epidemiology, 2010, 172, 578-590.	1.6	86
51	Glycosylation Variants of Mucins and CEACAMs As Candidate Biomarkers for the Diagnosis of Pancreatic Cystic Neoplasms. Annals of Surgery, 2010, 251, 937-945.	2.1	83
52	Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate, 2009, 69, 363-372.	1.2	80
53	A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. Journal of the National Cancer Institute, 2019, 111, 372-379.	3.0	79
54	Vitamin D pathway gene variants and prostate cancer prognosis. Prostate, 2010, 70, 1448-1460.	1.2	77

#	Article	IF	Citations
55	Increased Plasma Levels of the APC-Interacting Protein MAPRE1, LRG1, and IGFBP2 Preceding a Diagnosis of Colorectal Cancer in Women. Cancer Prevention Research, 2012, 5, 655-664.	0.7	77
56	Lung Cancer Risk Among Female Textile Workers Exposed to Endotoxin. Journal of the National Cancer Institute, 2007, 99, 357-364.	3.0	76
57	Three-Tiered Risk Stratification Model to Predict Progression in Barrett's Esophagus Using Epigenetic and Clinical Features. PLoS ONE, 2008, 3, e1890.	1.1	76
58	Impact of Work Site Health Promotion on Stages of Dietary Change: The Working Well Trial. Health Education and Behavior, 1998, 25, 448-463.	1.3	73
59	Telomere Length in the Colon Declines with Age: a Relation to Colorectal Cancer?. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 573-577.	1.1	73
60	Pro–Surfactant Protein B As a Biomarker for Lung Cancer Prediction. Journal of Clinical Oncology, 2013, 31, 4536-4543.	0.8	73
61	Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. Modern Pathology, 2016, 29, 904-914.	2.9	71
62	Canary Prostate Active Surveillance Study: Design of a Multi-institutional Active Surveillance Cohort and Biorepository. Urology, 2010, 75, 407-413.	0.5	70
63	A Multiparametric Panel for Ovarian Cancer Diagnosis, Prognosis, and Response to Chemotherapy. Clinical Cancer Research, 2007, 13, 6984-6992.	3.2	69
64	Genetic Variants in the *LEPR*, *CRY1*, *RNASEL*, *IL4*, and *ARVCF* Genes Are Prognostic Markers of Prostate Cancer-Specific Mortality. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1928-1936.	1.1	68
65	Multiple Independent Genetic Variants in the 8q24 Region Are Associated with Prostate Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1203-1213.	1.1	67
66	PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies. Pancreas, 2018, 47, 1229-1238.	0.5	67
67	Application of the Time-Dependent ROC Curves for Prognostic Accuracy with Multiple Biomarkers. Biometrics, 2006, 62, 279-287.	0.8	66
68	Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer. Clinical Cancer Research, 2017, 23, 311-319.	3.2	65
69	Evaluation of a novel saliva–based epidermal growth factor receptor mutation detection for lung cancer: A pilot study. Thoracic Cancer, 2016, 7, 428-436.	0.8	64
70	Correlated binomial variates: Properties of estimator of intraclass correlation and its effect on sample size calculation. Statistics in Medicine, 1992, 11, 1607-1614.	0.8	62
71	Salivary Biomarkers for Detection of Oral Squamous Cell Carcinoma in a Taiwanese Population. Clinical Cancer Research, 2016, 22, 3340-3347.	3.2	62
72	A Prospective Study to Establish a New-Onset Diabetes Cohort. Pancreas, 2018, 47, 1244-1248.	0.5	62

#	ARTICLE	IF	CITATIONS
73	Optimal Permutation Tests for the Analysis of Group Randomized Trials. Journal of the American Statistical Association, 2001, 96, 1424-1432.	1.8	61
74	Cancer prevention behaviors and socioeconomic status among Hispanics and non-Hispanic whites in a rural population in the United States. Cancer Causes and Control, 2002, 13, 719-728.	0.8	61
75	Vitamin D receptor gene polymorphisms and prostate cancer risk. Prostate, 2004, 59, 409-418.	1.2	61
76	Enhanced Discrimination of Malignant from Benign Pancreatic Disease by Measuring the CA 19-9 Antigen on Specific Protein Carriers. PLoS ONE, 2011, 6, e29180.	1.1	61
77	Early-Phase Studies of Biomarkers: What Target Sensitivity and Specificity Values Might Confer Clinical Utility?. Clinical Chemistry, 2016, 62, 737-742.	1.5	61
78	PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. European Urology Focus, 2016, 2, 180-188.	1.6	60
79	DNA Methylation Profiles of Lymphoid and Hematopoietic Malignancies. Clinical Cancer Research, 2004, 10, 2928-2935.	3.2	59
80	Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda. Clinical Gastroenterology and Hepatology, 2022, 20, 9-18.	2.4	58
81	Serum Protein Expression Profiling for Cancer Detection: Validation of a SELDI-Based Approach for Prostate Cancer. Disease Markers, 2004, 19, 185-195.	0.6	57
82	Evaluation of Known Oncoantibodies, HER2, p53, and Cyclin B1, in Prediagnostic Breast Cancer Sera. Cancer Prevention Research, 2012, 5, 1036-1043.	0.7	57
83	A multicenter study shows *PTEN* deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate, 2015, 75, 1206-1215.	1.2	55
84	Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene, 2005, 24, 732-736.	2.6	54
85	Genetic Polymorphisms in Inflammation Pathway Genes and Prostate Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 923-933.	1.1	54
86	Presence of Simian Virus 40 DNA Sequences in Human Lymphoid and Hematopoietic Malignancies and Their Relationship to Aberrant Promoter Methylation of Multiple Genes. Cancer Research, 2004, 64, 3757-3760.	0.4	53
87	The Early Detection Research Network's Specimen Reference Sets: Paving the Way for Rapid Evaluation of Potential Biomarkers. Clinical Chemistry, 2013, 59, 68-74.	1.5	50
88	The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 337-343.	0.8	45
89	Associations of Body Mass Index, Smoking, and Alcohol Consumption With Prostate Cancer Mortality in the Asia Cohort Consortium. American Journal of Epidemiology, 2015, 182, 381-389.	1.6	42
90	Improving the Quality of Biomarker Discovery Research: The Right Samples and Enough of Them. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 944-950.	1.1	41

#	Article	IF	Citations
91	Mediation of Adult Fruit and Vegetable Consumption in the National 5 A Day for Better Health Community Studies. Annals of Behavioral Medicine, 2008, 35, 49-60.	1.7	40
92	Biases Introduced by Choosing Controls to Match Risk Factors of Cases in Biomarker Research. Clinical Chemistry, 2012, 58, 1242-1251.	1.5	40
93	Reliability, effect size, and responsiveness of health status measures in the design of randomized and cluster-randomized trials. Contemporary Clinical Trials, 2005, 26, 45-58.	0.8	38
94	The Impact of Prostate Volume, Number of Biopsy Cores and American Urological Association Symptom Score on the Sensitivity of Cancer Detection Using the Prostate Cancer Prevention Trial Risk Calculator. Journal of Urology, 2013, 190, 70-76.	0.2	38
95	Prediction of patientâ€specific risk and percentile cohort risk of pathological stage outcome using continuous prostateâ€specific antigen measurement, clinical stage and biopsy Gleason score. BJU International, 2011, 107, 1562-1569.	1.3	36
96	Modeling, Estimation and Validation of Cotton Dust and Endotoxin Exposures in Chinese Textile Operations. Annals of Occupational Hygiene, 2006, 50, 573-82.	1.9	34
97	Validation Study of Genes with Hypermethylated Promoter Regions Associated with Prostate Cancer Recurrence. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1331-1339.	1.1	34
98	Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy. Clinical Epigenetics, 2016, 8, 97.	1.8	34
99	Conditional estimation of sensitivity and specificity from a phase 2 biomarker study allowing early termination for futility. Statistics in Medicine, 2009, 28, 762-779.	0.8	33
100	Specific Glycoforms of MUC5AC and Endorepellin Accurately Distinguish Mucinous from Nonmucinous Pancreatic Cysts. Molecular and Cellular Proteomics, 2013, 12, 2724-2734.	2.5	33
101	Addressing multilevel barriers to cervical cancer screening in Korean American women: A randomized trial of a communityâ€based intervention. Cancer, 2017, 123, 1018-1026.	2.0	32
102	*PTEN* loss is associated with prostate cancer recurrence and alterations in tumor DNA methylation profiles. Oncotarget, 2017, 8, 84338-84348.	0.8	32
103	A comparison of generalized linear mixed model procedures with estimating equations for variance and covariance parameter estimation in longitudinal studies and group randomized trials. Statistics in Medicine, 2001, 20, 3353-3373.	0.8	31
104	Occupational Exposures and Breast Cancer Among Women Textile Workers in Shanghai. Epidemiology, 2007, 18, 383-392.	1.2	31
105	Explaining community-level variance in group randomized trials. , 1999, 18, 539-556.		30
106	Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis. Cancer Epidemiology, 2013, 37, 666-670.	0.8	30
107	Toward Rigorous Data Harmonization in Cancer Epidemiology Research: One Approach. American Journal of Epidemiology, 2015, 182, kwv133.	1.6	30
108	Some design issues in a community intervention trial. Contemporary Clinical Trials, 2002, 23, 431-449.	2.0	28

#	Article	IF	Citations
109	Improving Biomarker Identification with Better Designs and Reporting. Clinical Chemistry, 2011, 57, 1093-1095.	1.5	28
110	Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients. PLoS ONE, 2015, 10, e0132343.	1.1	28
111	Ultra-Short Circulating Tumor DNA (usctDNA) in Plasma and Saliva of Non-Small Cell Lung Cancer (NSCLC) Patients. Cancers, 2020, 12, 2041.	1.7	28
112	Methylation analysis in spontaneous sputum for lung cancer diagnosis. Lung Cancer, 2014, 84, 127-133.	0.9	27
113	Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. American Journal of Gastroenterology, 2019, 114, 530-532.	0.2	27
114	Updating risk prediction tools: A case study in prostate cancer. Biometrical Journal, 2012, 54, 127-142.	0.6	26
115	Quantifying Peptide Signal in MALDI-TOF Mass Spectrometry Data. Molecular and Cellular Proteomics, 2005, 4, 1990-1999.	2.5	25
116	MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas. Cancer Prevention Research, 2015, 8, 1112-1119.	0.7	25
117	A Model for the Design and Construction of a Resource for the Validation of Prognostic Prostate Cancer Biomarkers. Advances in Anatomic Pathology, 2013, 20, 39-44.	2.4	24
118	A Gastric Glycoform of MUC5AC Is a Biomarker of Mucinous Cysts of the Pancreas. PLoS ONE, 2016, 11, e0167070.	1.1	24
119	Gene expression panel predicts metastaticâ€‘lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer. Molecular Oncology, 2017, 11, 140-150.	2.1	24
120	Adding Rigor to Biomarker Evaluationsâ€"EDRN Experience. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2575-2582.	1.1	24
121	Association of body mass index and risk of death from pancreas cancer in Asians. European Journal of Cancer Prevention, 2013, 22, 244-250.	0.6	23
122	Occupational Exposures and Ovarian Cancer in Textile Workers. Epidemiology, 2008, 19, 244-250.	1.2	22
123	The Importance of Test Positive Predictive Value in Ovarian Cancer Screening. Clinical Cancer Research, 2008, 14, 7574-7574.	3.2	22
124	Standard Operating Procedures for Biospecimen Collection, Processing, and Storage. Pancreas, 2018, 47, 1213-1221.	0.5	22
125	Contribution of a Blood-Based Protein Biomarker Panel to the Classification of Indeterminate Pulmonary Nodules. Journal of Thoracic Oncology, 2021, 16, 228-236.	0.5	22
126	Combining multiple biomarkers linearly to maximize the partial area under the ROC curve. Statistics in Medicine, 2018, 37, 627-642.	0.8	21

#	Article	IF	Citations
127	Validation of a novel model for the early detection of hepatocellular carcinoma. Clinical Proteomics, 2019, 16, 2.	1.1	21
128	Occupational risk factors for endometrial cancer among textile workers in Shanghai, China. American Journal of Industrial Medicine, 2008, 51, 673-679.	1.0	20
129	Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort. Prostate, 2016, 76, 1409-1419.	1.2	19
130	MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. PLoS ONE, 2016, 11, e0165236.	1.1	19
131	Classification versus association models: Should the same methods apply?. Scandinavian Journal of Clinical and Laboratory Investigation, 2010, 70, 53-58.	0.6	18
132	A Community-Based Randomized Trial of Hepatitis B Screening Among High-Risk Vietnamese Americans. American Journal of Public Health, 2017, 107, 433-440.	1.5	18
133	Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. European Urology Focus, 2019, 5, 54-61.	1.6	18
134	Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 677-682.	1.1	17
135	A two‐stage approach for dynamic prediction of time‐to‐event distributions. Statistics in Medicine, 2016, 35, 2167-2182.	0.8	17
136	A five‐CpG DNA methylation score to predict metastatic‐lethal outcomes in men treated with radical prostatectomy for localized prostate cancer. Prostate, 2018, 78, 1084-1091.	1.2	16
137	Serum Glycans as Risk Markers for Non–Small Cell Lung Cancer. Cancer Prevention Research, 2016, 9, 317-323.	0.7	15
138	DNA methylation and cis-regulation of gene expression by prostate cancer risk SNPs. PLoS Genetics, 2020, 16, e1008667.	1.5	15
139	Partially Supervised Learning Using an EM‐Boosting Algorithm. Biometrics, 2004, 60, 199-206.	0.8	14
140	Alpha-Fetoprotein in Early Hepatocellular Carcinoma. Gastroenterology, 2010, 138, 400-401.	0.6	13
141	Comparison of two correlated ROC curves at a given specificity or sensitivity level. Statistics in Medicine, 2016, 35, 4352-4367.	0.8	13
142	Potential Cost-Effectiveness of Risk-Based Pancreatic Cancer Screening in Patients With New-Onset Diabetes. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 451-459.	2.3	13
143	Statistical Considerations in Combining Biomarkers for Disease Classification. Disease Markers, 2004, 20, 45-51.	0.6	12
144	Copy number alterations are associated with metastatic-lethal progression in prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 494-506.	2.0	12

#	ARTICLE	IF	CITATIONS
145	Evaluation of Community-Intervention Trials via Generalized Linear Mixed Models. Biometrics, 2004, 60, 1043-1052.	0.8	10
146	Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for â€œlargeâ€•cribriform prostatic adenocarcinoma. Modern Pathology, 2022, 35, 1092-1100.	2.9	10
147	A fourâ€gene transcript score to predict metastaticâ€lethal progression in men treated for localized prostate cancer: Development and validation studies. Prostate, 2019, 79, 1589-1596.	1.2	8
148	Re: Lung Cancer Risk Among Female Textile Workers Exposed to Endotoxin. Journal of the National Cancer Institute, 2010, 102, 913-914.	3.0	7
149	Logistic regression analysis with standardized markers. Annals of Applied Statistics, 2013, 7, .	0.5	6
150	Estimation of smooth ROC curves for biomarkers with limits of detection. Statistics in Medicine, 2017, 36, 3830-3843.	0.8	6
151	Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosis. Human Pathology, 2022, 122, 84-91.	1.1	6
152	Boosting with missing predictors. Biostatistics, 2010, 11, 195-212.	0.9	5
153	Borrowing Information Across Populations in Estimating Positive and Negative Predictive Values. Journal of the Royal Statistical Society Series C: Applied Statistics, 2011, 60, 633-653.	0.5	5
154	LOGISTIC REGRESSION ANALYSIS WITH STANDARDIZED MARKERS. , 2013, 7, .		5
155	Unbiased Estimation of Biomarker Panel Performance When Combining Training and Testing Data in a Group Sequential Design. Biometrics, 2016, 72, 888-896.	0.8	4
156	Group sequential testing of the predictive accuracy of a continuous biomarker with unknown prevalence. Statistics in Medicine, 2016, 35, 1267-1280.	0.8	4
157	The risk of biopsy-detectable prostate cancer using the prostate cancer prevention Trial Risk Calculator in a community setting. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1464-1469.	0.8	3
158	Model-free Scoring System for Risk Prediction with Application to Hepatocellular Carcinoma Study. Biometrics, 2018, 74, 239-248.	0.8	3
159	Two-stage biomarker panel study and estimation allowing early termination for futility. Biostatistics, 2015, 16, 799-812.	0.9	2
160	Small Sample Inference for Clustered Data. Lecture Notes in Statistics, 2004, , 71-87.	0.1	2
161	Toward a Robust System for Biomarker Triage and Validation â€" EDRN Experience. , 2009, , 297-306.		2
162	Identifying settings when permutation tests have nominal size with paired, binary-outcome, group randomized trials. Journal of Nonparametric Statistics, 2003, 15, 653-663.	0.4	1

#	ARTICLE	IF	CITATIONS
163	Application of Multidimensional Selective Item Response Regression Model for Studying Multiple Gene Methylation in SV40 Oncogenic Pathways. Journal of the American Statistical Association, 2008, 103, 201-211.	1.8	1
164	Strategies for validating biomarkers using data from a reference set. Biostatistics, 2021, 22, 298-314.	0.9	1
165	Profiling High-Dimensional Protein Expression Using MALDI-TOF. , 2005, , 437-456.		1
166	Counting Advanced Precancerous Lesions as True Positives When Determining Colorectal Cancer Screening Test Specificity. Journal of the National Cancer Institute, 2022, 114, 1040-1043.	3.0	1
167	A multivariate parametric empirical Bayes screening approach for early detection of hepatocellular carcinoma using multiple longitudinal biomarkers. Statistics in Medicine, 2022, 41, 2338-2353.	0.8	1
168	Hybrid design evaluating new biomarkers when there is an existing screening test. Statistics in Medicine, 2021, 40, 2037-2054.	0.8	0
169	Personalized statistical learning algorithms to improve the early detection of cancer using longitudinal biomarkers. Cancer Biomarkers, 2022, 33, 199-210.	0.8	0
170	The COMPASS study: A prospective, randomized, multi-center trial testing the impact of a clinic-based intervention informing patients of colorectal cancer screening options on screening completion. Contemporary Clinical Trials, 2022, 119, 106852.	0.8	0